News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
The new program includes upstream and downstream process development and large-scale GMP production.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Cantourage introduces second Clever Leaves medical cannabis product to the German market
New Director supports NASDAQ rule on diversity
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Innate to receive $5M milestone payment from AstraZeneca
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Subscribe To Our Newsletter & Stay Updated
